1. Jara Rubio et al., Phase IIB, Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID-19
150 patient defibrotide late treatment RCT: 23% higher mortality (p=0.56), 200% higher progression (p=0.14), no change in ICU admission (p=1), and 18% longer hospitalization (p=0.41).RCT 150 hospitalized COVID-19 patients with respiratory failure showing no significant benefit with continuous IV defibrotide versus placebo.
May 2026, European J. Haematology, https://onlinelibrary.wiley.com/doi/10.1111/ejh.70214, https://c19p.org/jararubio